Alpha-linolenic acid increases cholesterol efflux in macrophage-derived foam cells by decreasing stearoyl CoA desaturase 1 expression: Evidence for a farnesoid-X-receptor mechanism of action

Journal of Nutritional Biochemistry

Volumn 23, Issue 4, 2012, Pages 400-409

  Zhang, Jun ^a   Kris Etherton, Penny M ^a   Thompson, Jerry T ^a   Hannon, Daniel B ^a   Gillies, Peter J ^b   Vanden Heuvel, John P ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b the State University of New Jersey   (United States)

Author keywords

ALA; Cholesterol efflux; Foam cell; FXR; SCD1; SREBP1C

Indexed keywords

ACYL COENZYME A DESATURASE 1; CHOLESTEROL; FARNESOID X RECEPTOR; HETERODIMER; LINOLENIC ACID; LIVER X RECEPTOR; SMALL INTERFERING RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C;

ANIMAL CELL; ARTICLE; CELL LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DIET THERAPY; ENZYME REGULATION; ENZYME REPRESSION; FOAM CELL; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIPID STORAGE; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

ALPHA-LINOLENIC ACID; ANIMALS; APOPTOSIS; CELL LINE; CHOLESTEROL; FATTY ACIDS, MONOUNSATURATED; FOAM CELLS; HEK293 CELLS; HUMANS; MACROPHAGES; ORPHAN NUCLEAR RECEPTORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, SMALL INTERFERING; STEAROYL-COA DESATURASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIGLYCERIDES;

EID: 84858294016     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2011.01.004     Document Type: Article

References (63)

1. U.S.Department of Health and Human Services, Agency for Healthcare Research and Quality Omega-3 fatty acids, effects on cardiovascular disease Accessed on December 18, 2009. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=hserta&part=A137995.
2. Sampath H., Ntambi J.M. Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annu Rev Nutr 2005, 25:317-340.
3. Nishimoto T., Pellizzon M.A., Aihara M., Stylianou I.M., Billheimer J.T., Rothblat G., et al. Fish oil promotes macrophage reverse cholesterol transport in mice. Arterioscler Thromb Vasc Biol 2009, 29:1502-1508.
4. Dusserre E., Pulcini T., Bourdillon M.C., Ciavatti M., Berthezene F. Omega-3 fatty acids in smooth muscle cell phospholipids increase membrane cholesterol efflux. Lipids 1995, 30:35-41.
5. Marmillot P., Rao M.N., Liu Q.H., Chirtel S.J., Lakshman M.R. Effect of dietary omega-3 fatty acids and chronic ethanol consumption on reverse cholesterol transport in rats. Metabolism 2000, 49:508-512.
6. Gillotte K.L., Lund-Katz S., de la Llera-Moya M., Parks J.S., Rudel L.L., Rothblat G.H., et al. Dietary modification of high density lipoprotein phospholipid and influence on cellular cholesterol efflux. J Lipid Res 1998, 39:2065-2075.
7. Kilsdonk E.P., Dorsman A.N., van Gent T., van Tol A. Effect of phospholipid fatty acid composition of endothelial cells on cholesterol efflux rates. J Lipid Res 1992, 33:1373-1382.
8. Murthy S., Born E., Mathur S.N., Field F.J. Liver-X-receptor-mediated increase in ATP-binding cassette transporter A1 expression is attenuated by fatty acids in CaCo-2 cells: effect on cholesterol efflux to high-density lipoprotein. Biochem J 2004, 377:545-552.
9. Wang Y., Oram J.F. Unsaturated fatty acids inhibit cholesterol efflux from macrophages by increasing degradation of ATP-binding cassette transporter A1. J Biol Chem 2002, 277:5692-5697.
10. Schmitz G., Langmann T. Transcriptional regulatory networks in lipid metabolism control ABCA1 expression. Biochim Biophys Acta 2005, 1735:1-19.
11. Yancey P.G., Bortnick A.E., Kellner-Weibel G., de la Llera-Moya M., Phillips M.C., Rothblat G.H. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003, 23:712-719.
12. Zhao G., Etherton T.D., Martin K.R., West S.G., Gillies P.J., Kris-Etherton P.M. Dietary alpha-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women. J Nutr 2004, 134:2991-2997.
13. Ntambi J.M., Miyazaki M. Recent insights into stearoyl-CoA desaturase-1. Curr Opin Lipidol 2003, 14:255-261.
14. Calder P.C., Bond J.A., Harvey D.J., Gordon S., Newsholme E.A. Uptake and incorporation of saturated and unsaturated fatty acids into macrophage lipids and their effect upon macrophage adhesion and phagocytosis. Biochem J 1990, 269:807-814.
15. Heinemann F.S., Ozols J. Degradation of stearoyl-coenzyme A desaturase: endoproteolytic cleavage by an integral membrane protease. Mol Biol Cell 1998, 9:3445-3453.
16. Chen G., Liang G., Ou J., Goldstein J.L., Brown M.S. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci U S A 2004, 101:11245-11250.
17. Vanden Heuvel J.P., Thompson J.T., Frame S.R., Gillies P.J. Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicol Sci 2006, 92:476-489.
18. Ntambi J.M. Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol. J Lipid Res 1999, 40:1549-1558.
19. Morisaki N., Kanzaki T., Fujiyama Y., Osawa I., Shirai K., Matsuoka N., et al. Metabolism of n-3 polyunsaturated fatty acids and modification of phospholipids in cultured rabbit aortic smooth muscle cells. J Lipid Res 1985, 26:930-939.
20. Pal S., Davis P.J. N-3 polyunsaturated fatty acids enhance cholesterol efflux from human fibroblasts in culture. Biochem Biophys Res Commun 1990, 173:566-570.
21. Mathur S.N., Watt K.R., Field F.J. Regulation of intestinal NPC1L1 expression by dietary fish oil and docosahexaenoic acid. J Lipid Res 2007, 48:395-404.
22. Sun Y., Hao M., Luo Y., Liang C.P., Silver D.L., Cheng C., et al. Stearoyl-CoA desaturase inhibits ATP-binding cassette transporter A1-mediated cholesterol efflux and modulates membrane domain structure. J Biol Chem 2003, 278:5813-5820.
23. Rudel L.L., Shelness G.S. Cholesterol esters and atherosclerosis-a game of ACAT and mouse. Nat Med 2000, 6:1313-1314.
24. Knapp H.R., Hullin F., Salem N. Asymmetric incorporation of dietary n-3 fatty acids into membrane aminophospholipids of human erythrocytes. J Lipid Res 1994, 35:1283-1291.
25. Spector A.A., Yorek M.A. Membrane lipid composition and cellular function. J Lipid Res 1985, 26:1015-1035.
26. Wassall S.R., Brzustowicz M.R., Shaikh S.R., Cherezov V., Caffrey M., Stillwell W. Order from disorder, corralling cholesterol with chaotic lipids. The role of polyunsaturated lipids in membrane raft formation. Chem Phys Lipids 2004, 132:79-88.
27. Sweet W.D., Schroeder F. Polyunsaturated fatty acids alter sterol transbilayer domains in LM fibroblast plasma membrane. FEBS Lett 1988, 229:188-192.
28. Bjorkhem I., Diczfalusy U., Lutjohann D. Removal of cholesterol from extrahepatic sources by oxidative mechanisms. Curr Opin Lipidol 1999, 10:161-165.
29. Wang Y., Oram J.F. Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a protein kinase C delta pathway. J Lipid Res 2007, 48:1062-1068.
30. Lawn R.M., Wade D.P., Garvin M.R., Wang X., Schwartz K., Porter J.G., et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 1999, 104:R25-31.
31. Langmann T., Klucken J., Reil M., Liebisch G., Luciani M.F., Chimini G., et al. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. Biochem Biophys Res Commun 1999, 257:29-33.
32. Costet P., Luo Y., Wang N., Tall A.R. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem 2000, 275:28240-28245.
33. Tall A.R., Yvan-Charvet L., Terasaka N., Pagler T., Wang N. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis. Cell Metab 2008, 7:365-375.
34. Oram J.F., Vaughan A.M. ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ Res 2006, 99:1031-1043.
35. Dobrzyn A., Ntambi J.M. Stearoyl-CoA desaturase as a new drug target for obesity treatment. Obes Rev 2005, 6:169-174.
36. Popeijus H.E., Saris W.H., Mensink R.P. Role of stearoyl-CoA desaturases in obesity and the metabolic syndrome. Int J Obes (Lond) 2008, 32:1076-1082.
37. MacDonald M.L., Singaraja R.R., Bissada N., Ruddle P., Watts R., Karasinska J.M., et al. Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice. J Lipid Res 2008, 49:217-229.
38. Savransky V., Jun J., Li J., Nanayakkara A., Fonti S., Moser A.B., et al. Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme A desaturase. Circ Res 2008, 103:1173-1180.
39. Brown J.M., Chung S., Sawyer J.K., Degirolamo C., Alger H.M., Nguyen T.M., et al. Combined therapy of dietary fish oil and stearoyl-CoA desaturase 1 inhibition prevents the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2010, 30:24-30.
40. MacDonald M.L., van Eck M., Hildebrand R.B., Wong B.W., Bissada N., Ruddle P., et al. Despite antiatherogenic metabolic characteristics, SCD1-deficient mice have increased inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol 2009, 29:341-347.
41. Brown J.M., Chung S., Sawyer J.K., Degirolamo C., Alger H.M., Nguyen T., et al. Inhibition of stearoyl-coenzyme A desaturase 1 dissociates insulin resistance and obesity from atherosclerosis. Circulation 2008, 118:1467-1475.
42. Fessler M.B., Rudel L.L., Brown J.M. Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome. Curr Opin Lipidol 2009, 20:379-385.
43. Warner G.J., Stoudt G., Bamberger M., Johnson W.J., Rothblat G.H. Cell toxicity induced by inhibition of acyl coenzyme A:cholesterol acyltransferase and accumulation of unesterified cholesterol. J Biol Chem 1995, 270:5772-5778.
44. Meuwese M.C., de Groot E., Duivenvoorden R., Trip M.D., Ose L., Maritz F.J., et al. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA 2009, 301:1131-1139.
45. Vanden Heuvel J.P. Diet, fatty acids, and regulation of genes important for heart disease. Curr Atheroscler Rep 2004, 6:432-440.
46. Miller C.W., Ntambi J.M. Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression. Proc Natl Acad Sci U S A 1996, 93:9443-9448.
47. Kim Y.C., Gomez F.E., Fox B.G., Ntambi J.M. Differential regulation of the stearoyl-CoA desaturase genes by thiazolidinediones in 3T3-L1 adipocytes. J Lipid Res 2000, 41:1310-1316.
48. Montanaro M.A., Lombardo Y.B., Gonzalez M.S., Bernasconi A.M., Chicco A., Rimoldi O.J., et al. Effect of troglitazone on the desaturases in a rat model of insulin-resistance induced by a sucrose-rich diet. Prostaglandins Leukot Essent Fatty Acids 2005, 72:241-250.
49. Yao-Borengasser A., Rassouli N., Varma V., Bodles A.M., Rasouli N., Unal R., et al. Stearoyl-coenzyme A desaturase 1 gene expression increases after pioglitazone treatment and is associated with peroxisomal proliferator-activated receptor-gamma responsiveness. J Clin Endocrinol Metab 2008, 93:4431-4439.
50. Riserus U., Tan G.D., Fielding B.A., Neville M.J., Currie J., Savage D.B., et al. Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma. Diabetes 2005, 54:1379-1384.
51. Toyama T., Kudo N., Hibino Y., Mitsumoto A., Nishikawa M., Kawashima Y. Effects of pioglitazone on stearoyl-CoA desaturase in obese Zucker fa/fa rats. J Pharmacol Sci 2007, 104:137-145.
52. Soria A., Gonzalez Mdel C., Vidal H., Herrera E., Bocos C. Triglyceridemia and peroxisome proliferator-activated receptor-alpha expression are not connected in fenofibrate-treated pregnant rats. Mol Cell Biochem 2005, 273:97-107.
53. Hebbachi A.M., Knight B.L., Wiggins D., Patel D.D., Gibbons G.F. Peroxisome proliferator-activated receptor alpha deficiency abolishes the response of lipogenic gene expression to re-feeding: restoration of the normal response by activation of liver X receptor alpha. J Biol Chem 2008, 283:4866-4876.
54. Montanaro M.A., Bernasconi A.M., Gonzalez M.S., Rimoldi O.J., Brenner R.R. Effects of fenofibrate and insulin on the biosynthesis of unsaturated fatty acids in streptozotocin diabetic rats. Prostaglandins Leukot Essent Fatty Acids 2005, 73:369-378.
55. Zhou J., Zhai Y., Mu Y., Gong H., Uppal H., Toma D., et al. A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J Biol Chem 2006, 281:15013-15020.
56. Thomas C., Pellicciari R., Pruzanski M., Auwerx J., Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008, 7:678-693.
57. Mencarelli A., Renga B., Distrutti E., Fiorucci S. Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol 2009, 296:H272-281.
58. Guo G.L., Santamarina-Fojo S., Akiyama T.E., Amar M.J., Paigen B.J., Brewer B., et al. Effects of FXR in foam-cell formation and atherosclerosis development. Biochim Biophys Acta 2006, 1761:1401-1409.
59. Zhang Y., Wang X., Vales C., Lee F.Y., Lee H., Lusis A.J., et al. FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice. Arterioscler Thromb Vasc Biol 2006, 26:2316-2321.
60. Torocsik D., Szanto A., Nagy L. Oxysterol signaling links cholesterol metabolism and inflammation via the liver X receptor in macrophages. Mol Aspects Med 2009, 30:134-152.
61. Horton J.D., Goldstein J.L., Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002, 109:1125-1131.
62. Brendel C., Schoonjans K., Botrugno O.A., Treuter E., Auwerx J. The small heterodimer partner interacts with the liver X receptor alpha and represses its transcriptional activity. Mol Endocrinol 2002, 16:2065-2076.
63. Chu K., Miyazaki M., Man W.C., Ntambi J.M., Stearoyl-coenzyme A. desaturase 1 deficiency protects against hypertriglyceridemia and increases plasma high-density lipoprotein cholesterol induced by liver X receptor activation. Mol Cell Biol 2006, 26:6786-6798.